Equillium
About: Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Employees: 45
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more capital invested
Capital invested by funds: $4.96M [Q2] → $5.72M (+$759K) [Q3]
0% more funds holding
Funds holding: 25 [Q2] → 25 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.89% less ownership
Funds ownership: 20.31% [Q2] → 19.42% (-0.89%) [Q3]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for EQ.
Financial journalist opinion
Based on 5 articles about EQ published over the past 30 days
